Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.29M P/E - EPS this Y - Ern Qtrly Grth -
Income -4.14M Forward P/E - EPS next Y 27.30% 50D Avg Chg 5.00%
Sales 507.2k PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 3.22 EPS next 5Y - 52W High Chg -72.00%
Recommedations 2.00 Quick Ratio 2.54 Shares Outstanding 8.10M 52W Low Chg 27.00%
Insider Own 35.49% ROA -93.77% Shares Float 4.67M Beta -
Inst Own 7.87% ROE -171.56% Shares Shorted/Prior 120.54K/48.77K Price 2.14
Gross Margin - Profit Margin - Avg. Volume 9,643 Target Price 2.00
Oper. Margin -697.93% Earnings Date - Volume 6,432 Change 1.90%
About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc. News
12/03/24 Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
11/21/24 Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
11/17/24 Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)
11/12/24 Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
11/01/24 Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
10/29/24 Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
10/15/24 Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
10/09/24 Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
09/25/24 PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
09/24/24 Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
08/27/24 Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
08/22/24 Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
08/21/24 Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
08/16/24 Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)
08/12/24 Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial
08/12/24 Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
08/01/24 Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
08/01/24 Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
07/29/24 Top Midday Gainers
07/29/24 Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients